FDA denies Lilly appeal

Article

The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Related Content
A photo of Prithvi Ramtohul, MD, who received the Ramin Tadayoni Award at the 2025 EURETINA Congress.

EURETINA grants Prithvi Ramtohul, MD, 2025 Ramin Tadayoni Award

Hattie Hayes
September 4th 2025
Article
Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
September 4th 2025
Podcast
A movie theatre with empty seats. The screen has reels of film negatives, with a blue tint, and the words "Coming Soon" in large yellow letters. Image credit: Created with Canva. Components via Photology2000 and Ron Lach, Pexels.

EURETINA industry previews: Beacon Therapeutics, Nanoscope Therapeutics and Valitor

Kassi Filkins
September 4th 2025
Article
A person stands in front of a white screen, facing an audience. The speaker and audience are visible in silhouette. Concept image for European Society of Retina Specialists (EURETINA) clinical trial data presentation. Logos courtesy of EURETINA, Ashvattha Therapeutics, Clearside Biomedical and Carl Zeiss Medical Technology. Background image courtesy of TezcanKemal, Getty Images. Created with Canva.

Ashvattha Therapeutics, Clearside Biomedical, ZEISS preview EURETINA presentations

Kassi Filkins
September 4th 2025
Article
An older woman with glasses on sits and reads a book, a mug of coffee in front of her. Concept image for geographic atrophy lesions (GA) and age-related macular degeneration (AMD). Image credit: ©MiguelAngel – stock.adobe.com

Progression rates vary in subtypes of geographic atrophy lesions

Lynda Charters
September 4th 2025
Article
A person speaks on a stage during a conference/lecture. Concept image for 2025 EURETINA European Society of Retina specialists scientific meeting. Image credit: ©Anton Gvozdikov – stock.adobe.com

The Eye Care Network's clinical advisors will present at EURETINA

Hattie Hayes
September 4th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.